The journal published a Special Focus issue documenting advancements in oncology since its debut in 2005. Review articles cover topics such as immunotherapy and stereotactic body radiotherapy, providing insights into the latest scientific and clinical issues in cancer research.
The ESMO Global Opioid Policy Initiative reveals disparities in opioid access across the globe, with the Middle East, Latin America, and Asia showing limited access to essential pain relieving medication. The addition of new Designated Centres brings polices tailored to patient needs, promoting a multidisciplinary approach to cancer care.
A new report highlights progress in treating childhood cancers, but notes that many survivors face long-term treatment-related side effects. The European Society for Paediatric Oncology proposes solutions to tackle these issues, including improving access to new drugs and enhancing collaboration with adult oncology.
The Montefiore-Einstein Center for Cancer Care has received a $3.93 million grant from the National Cancer Institute to support clinical oncology research. Four new scholars have been selected, including Drs. Thomas Ow and Akiva Novetsky, who will focus on radiation therapy and gynecologic oncology surgeries.
The American Society for Radiation Oncology (ASTRO) has awarded a total of $33,500 to 41 researchers for their outstanding contributions to the field of radiation oncology. The awards recognize top-rated abstracts presented at the 2015 Annual Meeting, with recipients receiving cash honors and complimentary registration.
Researchers create economic model to assess life expectancy, management of adverse effects, and quality of life for new oncology drugs like necitumumab. The study finds that the value-based price for necitumumab ranges between $563 and $1,309 per three-week cycle.
The American Society for Radiation Oncology has selected seven leading physician-researchers to receive a total of $675,000 in awards and grants to advance radiation oncology research. The recipients will support studies in radiation and cancer biology, as well as outcomes/health services research within radiation oncology.
The ESMO Women for Oncology Task Force aims to address inequalities among women oncologists, and the new award will be presented to Enriqueta Felip, who kick-started awareness of the lack of women oncologists in leadership roles. The award recognizes contributors who support the development of women in oncology.
A recent study published in the Journal of Geriatric Oncology found that 26% of senior oncology patients use complementary or alternative medicines, which can interact with cancer treatments. The study highlights the need for comprehensive screening and documentation of CAM use in older cancer patients.
The European Society for Medical Oncology (ESMO) announced the award of its esteemed prizes to three exceptional medical oncologists: Nathan Cherny, Nagahiro Saijo, and Cornelis Punt. These pioneers have made groundbreaking contributions to palliative care integration, medical oncology in Asia, and immunotherapy approaches.
Women with early-stage breast cancer who receive a shorter course of whole breast radiation therapy experience less toxicity and improved quality of life compared to those who undergo a longer course of treatment. The study suggests that hypofractionated treatment should be considered as a starting point for discussion between patients...
BMJ has partnered with the European Society for Medical Oncology (ESMO) to publish a new open access cancer journal called ESMO Open. The journal will cover various aspects of cancer treatment and include study protocols and phase I clinical trials. It aims to provide rapid access to high-quality research on cancer care worldwide.
A study published in JAMA Oncology found that chemotherapy was associated with worse quality of life near death for patients who could still perform many life functions. The researchers concluded that chemotherapy use may be unnecessary and potentially harmful for patients with progressive metastatic disease.
A large trial shows liquid biopsy (BEAMing technology) detects tumor genotypes not found in tissue biopsies, enabling targeted therapy selection. Regorafenib benefits patients with KRAS and PIK3CA mutations, revolutionizing colorectal cancer treatment.
A study of 76 patients with cervical or endometrial cancer found that extended-field IMRT did not increase duodenal toxicity risk, even at high doses. The study confirms the safety of EF-IMRT for treating para-aortic lymph nodes.
The American Society for Radiation Oncology (ASTRO) has launched a new open-access journal, Advances in Radiation Oncology, with Founding Editor Robert C. Miller, M.D. The journal will publish original research on novel retrospectives and hypothesis-generating series, with a focus on practice transformation.
Dr. Maurizio D'Incalci receives the first Pezcoller-Prodi Award in recognition of his work on translational cancer research and therapeutic oncology. The award highlights his contributions to the development of novel anticancer drugs, including trabectedin.
The American College of Cardiology seeks to expand cardio-oncology services to address the growing need for specialized care in cardiovascular health for cancer patients. Currently, many hospital training programs lack formal training or services in this area, and a nationwide survey reveals gaps in resources and best practices.
The newly redesigned Oncology Central is now live, featuring a dedicated Pipelines and Trials section, webinars, and exclusive multimedia content. The platform offers easy navigation and access to peer-reviewed journal articles, regular cancer news updates, and exciting features.
The ESMO Magnitude of Clinical Benefit Scale (ESMO-MCBS) provides a rational approach to grading the magnitude of clinical benefit of anti-cancer medicines. The scale will be applied to new drugs approved by the EMA, with high-scoring drugs highlighted in the ESMO Clinical Practice Guidelines.
A recent Mayo Clinic study found that combining the targeted drug ibrutinib with standard chemotherapy significantly reduces the risk of death or cancer progression in patients with relapsed CLL or SLL. The treatment results in a nearly 80% reduction in mortality, offering new hope for longer disease control and decreased risk of relapse.
The American Society for Radiation Oncology (ASTRO) has issued a new guideline on definitive and adjuvant radiotherapy in locally advanced non-small cell lung cancer, citing 35 years of data to guide current treatment and future research. The guideline recommends RT as the ideal treatment for patients with locally advanced NSCLC.
The Global Cancer Project Map is an online resource connecting the global cancer community, enabling access to cancer projects and expertise. The map covers a range of projects, from prevention to palliative care, and aims to reduce health disparities and strengthen human capital in underserved areas.
The International Lymphoma Radiation Oncology Group (ILROG) has issued a guideline outlining the use of 3D computed tomography-based radiation therapy planning and volumetric image guidance to treat pediatric Hodgkin lymphoma. The guidelines aim to reduce radiation dose to normal tissue and decrease the risk of late side effects.
A study in Lancet Oncology suggests continued treatment with YONDELIS for advanced soft-tissue sarcoma patients who have not progressed after six courses improves progression-free survival. The results also indicate that a drug holiday may worsen outcomes.
A new standard of care for soft tissue sarcomas has been established through a study that shows image-guided radiotherapy can reduce long-term side effects while maintaining survival rates. The treatment delivers smaller radiation doses to tumors, minimizing exposure to surrounding healthy tissue.
The American Society of Clinical Oncology (ASCO) announces its cancer Advance of the Year, four new treatments improving outlook for patients with chronic lymphocytic leukemia (CLL). New therapies include immunotherapy drugs and molecularly targeted drugs offering more effective treatment options.
A 2013 survey of radiation oncologists found that peer review is a common practice in medicine, but there is wide variation in its performance. Seventy-eight percent of respondents reported being involved in peer review, and 74% expressed interest in formal guidelines to improve the process.
Neoplasia and Translational Oncology, two leading open-access cancer research journals, are now published by Elsevier. These peer-reviewed journals feature studies on novel investigations in oncology research, providing important data for advancing cancer diagnosis and treatment.
A new study published in the Journal of Clinical Oncology found that the risk of developing leukemia after radiation therapy or chemotherapy for early-stage breast cancer is twice as high as previously reported. The study analyzed data from 20,063 breast cancer patients and found a cumulative risk of 0.5 percent.
A study by Ohio State University researchers found that patients treated at highly-experienced radiation oncology centers had better survival rates and fewer cancer recurrences compared to those treated at less experienced centers. The study analyzed data from 470 patients treated with radiation therapy between 2002-2005.
A study by Ben-Gurion University of the Negev found that preclinical oncology courses increased students' interest in specializing in oncology and empathy for cancer patients. The research suggests a need for medical schools to include such curriculum to develop communication skills and sensitivity towards death and dying.
Research reveals that minimally invasive adenocarcinoma (MIA) and adenocarcinoma in-situ (AIS) lung cancer patients have comparable five-year disease-free and overall survival rates of 97.7%. This finding suggests that tumor sub-classification may not provide additional prognostic information for patients with tumors ≤3 cm in size.
Analysis of over 600 small cell lung cancer and neuroendocrine tumors identified common molecular markers, including EGFR amplification, that could reveal new therapeutic targets. The study found notable differences in biomarker expression between SCLC and NET tumors.
A 10-year analysis of data from an institutional patient registry indicates that 79% of tumors are controlled locally for early stage lung cancer patients treated with SBRT. The treatment resulted in minimal toxicity, with no grade 4 or 5 events recorded.
Research found that post-operative radiation therapy improved overall survival for patients with resected NSCLC, with a median survival time of 42 months compared to 38 months without PORT. Factors associated with better survival included female gender, adenocarcinoma histology, and younger age.
A study analyzing Medicare claims found that biopsies accounted for 43.1% of $38.3 million in diagnostic costs for patients with ultimately negative lung cancer diagnoses. Lung biopsies were also the most expensive test, with a median cost of $3,784 and an average cost including complications of $37,745.
Research shows that primary care providers who know guideline recommendations for low-dose computed tomography (LDCT) screening are more likely to order LDCT for high-risk individuals. This knowledge gap is highlighted by a survey of over 200 primary care providers, which found that 48% knew three or more guideline components.
A study published in Practical Radiation Oncology evaluated the use of image-guided radiation therapy (IGRT) in treating pediatric cancers. The results show that IGRT is commonly used to improve localization and precision in radiation delivery, particularly for tumors near sensitive structures or organs.
The University of Hawai`i Cancer Center has received a $3.5 million NCORP grant to improve cancer care and prevention among minority and underserved populations in Hawaii. The grant will fund clinical trials and research aimed at reducing cancer disparities and enhancing patient outcomes.
A study published in Journal of Clinical Oncology found that the 2005 Medicare law had no significant impact on reducing chemotherapy drug costs, contradicting economists' expectations. Instead, cancer care costs skyrocketed during the decade after the law passed.
A survey of 80 female Greek oncologists found that women are under-represented in leadership positions, with team leaders being men in 82% of cases. The European Society for Medical Oncology launches a new initiative to promote the exchange of ideas among female oncologists and support women with cancer.
A survey of 895 doctors in Europe, South America, and Asia revealed that over three-quarters of oncology specialists believe their patients are not well-informed about treatment options. The majority (90%) use biomarker testing to choose treatments, but many identify cost or lack of reimbursement as key barriers.
A survey of 595 young oncologists found that 71% are at risk of developing burnout, a syndrome characterized by emotional exhaustion and depersonalization. The study highlights the need for action to address burnout across all levels, from universities to professional societies.
A new research study reveals that many patients with advanced, incurable cancer do not receive palliative care, despite the presence of designated centres promoting integrated oncology and care. The study found significant gaps in palliative care delivery, highlighting the need for increased budget allocation.
Charlie Ma, Ph.D., a Professor and Director of Medical Physics at Fox Chase Cancer Center, has been selected as an ASTRO Fellow. He is recognized for his contributions to the field of radiation oncology, including research, education, and patient care.
The European Society of Cardiology has launched newregistries for cardiac oncology and ACS, aiming to monitor treatment practices and outcomes. The registries will provide robust data on cardiovascular disease burden and treatment in Europe.
The European Society for Medical Oncology (ESMO) recognizes the contributions of three outstanding individuals in cancer research and treatment. Carsten Bokemeyer receives the ESMO Award for his work on malignant germ cell tumours, while Peter Boyle wins the Lifetime Achievement Award for his long-standing contribution to cancer epidem...
The American Society for Radiation Oncology (ASTRO) has awarded a total of $35,500 in individual grants to 43 researchers presenting at the 2014 Annual Meeting. The awards recognize top radiation oncology research from around the world and provide insight into significant advances in technology and biology.
Seven physicians receive funding to advance radiation oncology research, including studies on cancer biology, physics, and treatment outcomes. Recipients will focus on improving radiation therapy and enhancing patient care.
ASTRO Gold Medal winners Mary K. Gospodarowicz, Leonard L. Gunderson, and Nancy J. Tarbell will receive the award for their outstanding work in research, clinical care, teaching, and service. They have made significant contributions to advancing radiation oncology, improving patient outcomes, and promoting global health.
The American Society of Clinical Oncology recognizes MD Anderson leaders Gabriel Hortobagyi, Waun Ki Hong, and John Mendelsohn for their significant contributions to cancer research. Mendelsohn is known for his discovery of the monoclonal antibody Erbitux, while Hong has made groundbreaking advances in treating head and neck cancers.
Researchers at Mount Sinai present promising findings on innovative treatments for recurrent ovarian cancer, molecular profiling of bile duct and gallbladder cancers, and adjuvant therapy for melanoma. The studies demonstrate encouraging results for patients with these rare and often fatal diseases.
Leslie L. Robison, a St. Jude Children's Research Hospital researcher, has received the Pediatric Oncology Award for his contributions to childhood cancer survivorship research. Studies funded by Robison have shown that childhood cancer survivors are at an increased risk of developing new cancers and chronic health problems.
Dr. Neal Meropol, Chief of Hematology and Oncology at Case Western Reserve University, is honored as an ASCO Fellow for his exceptional volunteer service and dedication to cancer care. He has served on the ASCO Board of Directors and various committees, contributing to the organization's mission to improve cancer care.
Dr. Beverly Lange, a retired CHOP oncologist, is honored with the ASPHO Distinguished Career Award for her groundbreaking research on pediatric leukemia. Her contributions have significantly improved treatment outcomes, increasing survival rates to over 55%.
Beaumont Children's Hospital has been awarded a $20,000 grant from CureSearch to support therapeutic clinical trials for children with cancer. The hospital believes that clinical trials are essential in helping children with cancer, and this funding will enable them to open additional studies and reach more patients.
A patient diagnosed with advanced, incurable lung cancer was found to have early stage, curable lung cancer after stopping a rare antibiotic that caused liver and lung damage. The team's findings suggest that toxicity due to the antibiotic may be mistaken for cancer spread.
The American Society for Radiation Oncology (ASTRO) has issued a new guideline detailing the use of adjuvant radiation therapy in treating endometrial cancer. The guideline recommends postoperative external beam radiation for patients with early-stage disease, and vaginal cuff brachytherapy for those at high risk of vaginal recurrence.
A recent study found that the ICD-10 transition led to significant information loss, affecting about 8 percent of Medicaid codes. Financial implications also emerged, with 39 codes accounting for 2.9 percent of total Medicaid reimbursements and 5.3 percent of UI Cancer Center billing charges.